GPR65 and Hepatic fibrosis: Similar to the results of the BDL model, compared to the WT mice, the GPR65-KO mice exhibited markedly decreased hepatic fibrosis following CCl4 treatment, as measured by HE staining, Sirius red staining, Masson’s trichrome staining, IHC, Western blotting and qRT-PCR for pro-fibrotic genes, as well as liver hydroxyproline content (Fig. 3a–d).